Genetic and clinical predictors of warfarin dose requirements in African Americans. - Wikidata - awgldk - TriplyDB

Genetic and clinical predictors of warfarin dose requirements in African Americans.

Genetic and clinical predictors of warfarin dose requirements in African Americans.

http://www.wikidata.org/entity/Q43195085

about

Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Pharmacogenomics of hypertension and heart disease Warfarin pharmacogenetics: does more accurate dosing benefit patients?Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis Pharmacology of anticoagulants used in the treatment of venous thromboembolism Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin Warfarin Pharmacogenetics: New Life for an Old Drug Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans Pharmacogenetics of warfarin: challenges and opportunities.Implementing genotype-guided antithrombotic therapy.Genotype-based dosing algorithms for warfarin therapy: data review and recommendations.African American patients with gout: efficacy and safety of febuxostat vs allopurinol.Mapping genes that predict treatment outcome in admixed populations Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients PharmGKB summary: very important pharmacogene information for CYP4F2 Warfarin pharmacogenetics.Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.Genetic warfarin dosing: tables versus algorithms.Clinically relevant genetic variations in drug metabolizing enzymes.Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis Pharmacogenomics: application to the management of cardiovascular disease Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin.Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans.Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU Race influences warfarin dose changes associated with genetic factors.A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics.Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin.Factors affecting time to maintenance dose in patients initiating warfarin.Genome-wide association study of warfarin maintenance dose in a Brazilian sample The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review.The future of warfarin pharmacogenetics in under-represented minority groups.Warfarin pharmacogenetics: challenges and opportunities for clinical translation.Role of cytochrome P450 genotype in the steps toward personalized drug therapy.Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians.Pharmacogenomics of warfarin in populations of African descent.Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium

P2860

Q26823542-DC7F6E30-9329-4892-975A-0A2213BDBCE8 Q27015722-575F2765-2B84-45F9-A45D-5C8A1E2ADF3D Q27027304-18EF22C4-5837-47F1-970C-A0C277FF4787 Q28071310-004C8757-5B6F-4E0F-A079-80C494D5399B Q28078967-065931BF-B44E-4F40-9CFF-B3CBD56C03B6 Q28083875-B020DC1C-79EB-4AFE-9FA9-DF16E7C4A388 Q28276514-283103EE-05E0-4D07-B77B-A688A7579133 Q28468726-4453222C-EFA4-4960-A409-AC75973989CB Q33591111-CB62507A-D902-4BDB-B4BB-69E3F0A406B5 Q33819050-2F1AADC7-AB0C-4513-8A02-799CDA03B4DB Q33990428-2FD73745-2A3B-41C3-92D9-B15A5890AD7D Q34065133-78F65C4B-F54E-4149-BB41-00732D35B090 Q34153554-93278932-3014-4BB3-8743-FC9C8F900326 Q34348337-B32395F1-F753-4E7B-99E4-95009B431BB9 Q34571746-40C05130-949F-4270-A582-516488169438 Q34664072-C87E6091-3BEE-4157-BB20-6AC56C3E673F Q34785072-B412BBFB-238E-48A7-A56A-9EC27E0CDD18 Q34791041-78F7DE6B-354E-4DDC-BC47-913CFFB51D95 Q35021027-CD1313C0-53CF-4E08-A86A-2DA2CC5B7CC2 Q35032378-A481FAB8-50E5-4A92-808C-8C1DE1DEE1BC Q35185164-8385E5FF-9592-4DA9-8C29-2644C7ADC106 Q35309161-1DA0F0D8-5E94-498A-88CC-D0691DD069FD Q35639536-865C4B87-0815-4B48-A383-1D30428FD24A Q35661209-F258B8C9-A8E1-4279-8354-028D53D06211 Q35681000-F4914C02-34FA-46F3-9456-65A24A52B2F6 Q35795982-BB01A9CA-FA22-4B24-948B-8E5BB6E19CE0 Q35884265-90BBFD89-00EA-49B5-A679-12E8A6E5CBD4 Q35888757-6D9BF5D6-78E2-4595-8392-8F4353C4EEBE Q35991881-D38AB236-3437-4769-83B9-C4793F19ECD9 Q36015458-AA2D5A45-4E38-4AF2-A23A-4DB74E62CB12 Q36060109-B509A3FA-5A89-43E8-9FC0-D410D662D571 Q36068687-FFF0DD6A-191B-4810-8BF2-5579AC92B01A Q36228428-B4152460-C361-40D6-A96E-F7A7D0D6A426 Q36294461-78009179-635B-424A-9752-8A7E55EA6A99 Q36375431-B714D3EA-504C-4B5D-954B-4DD544027C98 Q36441521-3BEE5E2B-D4B1-46CB-A5B4-C4E715B19A65 Q36511894-93E18232-04F3-4A66-9658-4284D7A77EEB Q36599219-D59EBB2B-A8F3-4399-B598-DC7A80ACD5E8 Q36629209-9BB00D28-F81A-4BC2-B49D-42121126FCA1 Q36630081-8A89C0B4-21C1-4C22-B040-C66FC65690E9

P2860

Genetic and clinical predictors of warfarin dose requirements in African Americans.

http://www.wikidata.org/entity/Q43195085

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Genetic and clinical predictors of warfarin dose requirements in African Americans.

@en

Genetic and clinical predictors of warfarin dose requirements in African Americans.

@nl

type

label

Genetic and clinical predictors of warfarin dose requirements in African Americans.

@en

Genetic and clinical predictors of warfarin dose requirements in African Americans.

@nl

prefLabel

Genetic and clinical predictors of warfarin dose requirements in African Americans.

@en

Genetic and clinical predictors of warfarin dose requirements in African Americans.

@nl

P1433

Q43195085-1950C4B9-A687-43CD-9F35-D46413F906D7

P1476

Q43195085-D941FF7F-F5CA-4795-B9C2-23A4816CFBCB

P2093

Q43195085-0F7C7D2E-DE5D-4249-829A-D50F1DA18CEF

Q43195085-25955A53-E4E3-4173-B30D-A3AC9C4A1F5D

Q43195085-27C17034-68A6-43B8-853D-821DB21E29CD

Q43195085-29BE603C-6541-4FDD-BD94-7147FE6016EB

Q43195085-3F6D6637-D944-44E3-ACA9-4CB80E4F41F3

Q43195085-87948395-C95E-4345-B50E-11107F93AADF

Q43195085-B40030AD-6A44-476D-9A40-6E7D93965983

Q43195085-C50C098A-4B89-4FCF-A7B5-51E3B936689C

Q43195085-E0E134F6-5D0A-45E9-87A0-25B3C3EB2476

P2860

Q43195085-04A0D31C-8584-42A7-A06D-336E91D026EF

Q43195085-091CE1F6-D7B7-4635-B2EE-D110C069E0E3

Q43195085-0F7DD8CB-C282-485B-92DC-E7782C3D7C77

Q43195085-1169D00E-B621-440D-BAA9-52B4EA9570D6

Q43195085-365A3AD8-FC02-497C-9481-F578A375A280

Q43195085-3F29EC68-634D-4916-9256-C5099703887D

Q43195085-40D8CB3E-6C24-4BDB-A374-BB1FFD7C404C

Q43195085-4D8CCBAC-40B8-4D84-914D-FF93298B33BA

Q43195085-4DAADCD2-057F-4924-BB88-8FD11823A57A

Q43195085-4DD0985E-4720-4700-AFDB-394BF29123E3

P304

Q43195085-8A63AB39-0CD1-4B8B-A5C7-7ABF90169509

P31

Q43195085-88A36781-E083-460E-BCFF-95409286E302

P356

Q43195085-021DD899-C44D-4F21-867C-A387E23F250B

P407

Q43195085-49B55769-B94D-4DE4-B238-3F88BA52C45A

P433

Q43195085-1C37E33C-3194-4C37-BA59-3C19856B93B5

P478

Q43195085-93F1355A-BC5F-4537-BB00-464EC7BB038F

P577

Q43195085-4A161FE9-958D-4E3E-91C3-EE104079486A

P698

Q43195085-4DF81E1D-92C2-4625-A8BF-6ECCA470012D

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Genetic and clinical predictors of warfarin dose requirements in African Americans.

@en

P2093

E A Nutescu

http://www.w3.org/2001/XMLSchema#string

J A Johnson

http://www.w3.org/2001/XMLSchema#string

K M Momary

http://www.w3.org/2001/XMLSchema#string

L H Cavallari

http://www.w3.org/2001/XMLSchema#string

M A G Viana

http://www.w3.org/2001/XMLSchema#string

N L Shapiro

http://www.w3.org/2001/XMLSchema#string

S R Patel

http://www.w3.org/2001/XMLSchema#string

T Y Langaee

http://www.w3.org/2001/XMLSchema#string

W A Coty

http://www.w3.org/2001/XMLSchema#string

P2860

CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

Comprehensive human genome amplification using multiple displacement amplification.

Estimation of the warfarin dose with clinical and pharmacogenetic data.

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

CYP4F2 genetic variant alters required warfarin dose

Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E.

Association of warfarin dose with genes involved in its action and metabolism.

Evaluation of genetic factors for warfarin dose prediction

Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

P304

459-464

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2009.223

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20072124

http://www.w3.org/2001/XMLSchema#string